The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study

The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study

Abstract Objectives The irreversible epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) afatinib and dacomitinib are approved for first-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). We aimed to compare the efficacy and safety of afatinib and dacomi...

Full description

Bibliographic Details
Main Authors: Wen-Chien Cheng, Chi-Chien Lin, Wei-Chih Liao, Yu-Chao Lin, Chia-Hung Chen, Hung-Jen Chen, Chih-Yen Tu, Te-Chun Hsia
Format: Article
Language:English
Published: BMC 2024-02-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer (NSCLC)
Epidermal growth factor receptor (EGFR)
Dacomitinib
Afatinib
Online Access:https://doi.org/10.1186/s12885-024-11956-w

Similar Items

Similar Items